Rapt Therapeutics (NASDAQ:RAPT) Receives Average Rating of “Hold” from Analysts

Rapt Therapeutics (NASDAQ:RAPT) has been assigned an average rating of “Hold” from the thirteen ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $48.4444.

RAPT has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapt Therapeutics in a research note on Thursday, January 22nd. Barclays cut Rapt Therapeutics from an “overweight” rating to an “equal weight” rating and set a $58.00 target price on the stock. in a research report on Wednesday, January 21st. TD Cowen downgraded shares of Rapt Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Piper Sandler cut Rapt Therapeutics from an “overweight” rating to a “neutral” rating and set a $58.00 price target for the company. in a research note on Tuesday, January 20th. Finally, Clear Str downgraded Rapt Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th.

Rapt Therapeutics Price Performance

NASDAQ:RAPT opened at $58.02 on Thursday. The business has a 50 day simple moving average of $49.05 and a 200-day simple moving average of $33.85. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -5.25 and a beta of 0.49. Rapt Therapeutics has a 1 year low of $5.67 and a 1 year high of $58.02.

Institutional Trading of Rapt Therapeutics

Several large investors have recently bought and sold shares of RAPT. Invesco Ltd. increased its stake in Rapt Therapeutics by 18.8% during the 4th quarter. Invesco Ltd. now owns 167,030 shares of the company’s stock valued at $5,657,000 after purchasing an additional 26,486 shares in the last quarter. ADAR1 Capital Management LLC increased its position in shares of Rapt Therapeutics by 0.4% in the 4th quarter. ADAR1 Capital Management LLC now owns 509,679 shares of the company’s stock valued at $17,263,000 after acquiring an additional 1,908 shares during the period. XTX Topco Ltd acquired a new position in shares of Rapt Therapeutics in the 4th quarter valued at $616,000. Voloridge Investment Management LLC purchased a new position in Rapt Therapeutics in the 4th quarter worth $233,000. Finally, Virtus Investment Advisers LLC acquired a new stake in Rapt Therapeutics during the 4th quarter worth about $245,000. Hedge funds and other institutional investors own 99.09% of the company’s stock.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.